Menu +

Advancing the Study of Competitive GR Antagonists

Investigators are studying mifepristone and compounds from our next generation of competitive GR antagonists to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. This research addresses a variety of pre-clinical models and potential indications.

Clinical research with mifepristone

  • Alcohol dependence
  • Anti-psychotic drug induced weight gain
  • Prostate, ovarian, and breast cancers in combination with an anti-cancer agent
  • Cognitive enhancement in late life anxiety disorders
  • Post-traumatic stress disorder
  • Effects of Mifepristone on Biomarkers of Metabolic Function and Neuropsychological Performance among Older Middle-Aged Overweight/Obese Individuals

Basic research with mifepristone and/or Corcept’s proprietary competitive GR antagonists

  • Alcohol dependence
  • Amyotrophic lateral sclerosis (Lou Gehrig’s disease)
  • Alzheimer’s disease
  • Anti-psychotic induced weight gain
  • Breast cancer in combination with a chemotherapeutic agent
  • Electroconvulsive shock-induced retrograde amnesia
  • GR mechanistic studies
  • Metabolic syndrome
  • Muscular dystrophy
  • Obesity
  • Ovarian and prostate cancer
  • Prevention of glucocorticoid-induced neurological damage in premature infants
  • Stress disorders

Mifepristone Molecule

Mifepristone modulates the effects of cortisol by binding to the glucocorticoid receptor (in green).

Prolonged exposure to high levels of cortisol and disordered cortisol rhythms adversely affect systems throughout the body, and can cause serious, sometimes life-threatening conditions.

You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue